Coherus BioSciences, Inc (CHRS) Net earnings per share growth forecast for next year

Corporate company logo of Coherus Biosciences (CHRS)

Growing physician confidence in new cancer therapy methods is driving the projected EPS growth chart for Coherus Biosciences (CHRS) for the coming year, where the 15.50 mark serves as the current benchmark. The business is transitioning from biosimilars to innovation, leveraging profits from analogs. Efficiency is increasing through a unified sales network that eliminates redundant marketing expenses.

Coherus BioSciences, Inc (CHRS): Net earnings per share growth forecast for next year from 07/04/2022 to 11/17/2026

Summary analytical data breakdowns for Coherus (CHRS)

- share price and consensus valuation forecast:
Fundamental company analysis:Coherus BioSciences, Inc
Finished products of Coherus BioSciences Inc.

Coherus Biosciences (CHRS) is shifting from mass-market biosimilars toward the development of proprietary oncology drugs to combat pricing erosion. This indicator measures the percentage change in expected earnings per share (EPS) for the coming year, aggregating forecasts from leading analysts. The metric allows investors to assess the monetization potential of new antibodies relative to current costs. Use the company's projected EPS trend for the next year as a benchmark for timely portfolio adjustments.

Competitor analysis for Coherus Biosciences

INCY (incyte.com) - Earnings growth forecast for next year|Expected net earnings per share growth next year hutch-med.com HCM|Net earnings per share growth forecast for next year Nuvation Corp (NUVB)|DAWN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Monopar Pharma MNPR|Inhibrx Corp - Net earnings per share growth forecast for next year|IMAB - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Fennec Pharmaceuticals|HRTX: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Nuvectis NVCT|Expected earnings per share growth for next year CRBP|Expected net earnings per share growth next year Cardiff Oncology CRDF|Expected earnings per share growth for next year BYSI (BeyondSpring Inc.)|BCAB (BioAtla Corp) - Expected earnings per share trend next year|Lixte Biotechnology - Expected earnings per share growth for next year|Projected earnings per share increase next year CTXR (Citius Pharma)|Cellectar - Earnings growth forecast for next year|Expected earnings per share trend next year BLRX (BioLineRx Corp)|CANF: Earnings growth forecast for next year|Expected net earnings per share growth next year Aprea (APRE)|Net earnings per share growth forecast for next year kaziatherapeutics.com|SLXN: Expected earnings per share trend next year|Earnings growth forecast for next year NCNA|Earnings growth forecast for next year Chimerix Inc (CMRX)|Net earnings per share growth forecast for next year Cyclacel Pharmaceuticals Inc. CYCC|GTHX (g1therapeutics.com) - Net earnings per share change forecast for next year|KRON: Expected earnings per share growth for next year|Expected net earnings per share growth next year Kintara Therapeutics Inc|oncternal.com (ONCT) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year PRTG (Portage Biotech Corp)